medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2016, Number 1

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2016; 33 (1)

Linfoma de Hodgkin. Factores Pronósticos Asociados a la Respuesta del Tratamiento

Covarrubias-Espinoza G, Luna-Cordova JA, Rendón-García H, Gómez Maqueo-Chew A, Morales-Peralta A, Larios-Farak T, Ríos-García CG

Language: Spanish
References: 14
Page: 9-13
PDF size: 273.62 Kb.


ABSTRACT

Background: Hodgkin lymphoma (HL) is the second cause of childhood cancer in Mexico. Nowadays, most children and adolescents with HL can be cured. This challenges us to look beyond survival rates and find the true impact of prognostic factors for relapsed disease, which should be used as part of the risk-adapted therapy.
Objectives: Identify prognosis factors associated to the treatment in children with HL. Evaluate chemotherapy and radiotherapy treatment. Analyze relapse as a result of an unfavorable prognosis of HL.
Methodology: A retrospective analysis of the medical records of 21 patients with HL from “Hospital Infantil del Estado de Sonora” in a 10-year period. The variables of sex, age, clinic stage, histological type, tumor, B symptoms, early response, and relapse were analyzed.
Results: The survival free diseases a 2.4 years was 95.2%. The overall relapse was 38.1% and 50% of relapses were to the primary site. Overall mortality was 4.76% (n=1). Male, clinical stage, presence of B symptoms, Bulky size and unfavorable early response are adverse prognostic factors.
Conclusion: Important clinical stage reductions were observed at diagnosis: only thirty percent were diagnosed at advanced stages. Chemotherapy and radiotherapy are effective. Combined radiotherapy (second-line treatment) and hybrid therapy can be used with relapse high-risk or partial response patients and is also effective in the treatment of pediatric HL.


REFERENCES

  1. 1.- Moreno F, Dussel V, Abriata G, Loria D. Registro Oncopediátrico Hospitalario Argentino. Incidencia 2000-2009. Supervivencia 2000-2007. Tendencia de mortalidad 1997-2010. Primera Ed. 2012.

  2. 2.- Mack TM, Cozen W, Shibata DK. Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young adult form of the disease. N Engl J Med 1995; 332: 413.

  3. 3.- Covarrubias G, Incidencia del cáncer pediátrico 1979-2013. Servicio de Oncología. Bol Clin Hosp Infant Edo Son 2013; 28(1): 12.

  4. 4.- Centro para la Salud de la Infancia y Adolescencia (CeNSIA). Cáncer Infantil en México. [Consultado agosto 2015]. Disponible en: http://www.censia.salud.gob.mx/contenidos/cancer/interm_cancer.html.

  5. 5.- Robison LL, Stoker V, Frizzera G. Hodgkin’s disease in pediatric patients with naturally occurring immunodeficiency. Am J PediatrHematolOncol 1987; 9 (2):189.

  6. 6.- Donaldson SS. Finding the Balance in Pediatric Hodgkin’s Lymphoma. J ClinOncol 2012; 30(26):3158.

  7. 7.- Smith MA. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J ClinOncol 2010; 28 (15): 2625.

  8. 8.- Covarrubias G, Rendón H, Esquer O. Masa mediastinal gigante en adolescentes con linfoma Hodgkin. Bol Clin Hosp.Infant.Edo Son 2012; 29(1): 29.

  9. 9.- Sociedad Española de Oncología Médica. Generalidades de linfoma de Hodgkin, marzo 2013. [Consultado noviembre de 2014]. Disponible en: http://www.seom.org/en/informacion-sobre-el-cancer/info-tipos- cancer/linfomas-ymieloma/ linfoma-hodgkin.

  10. 10.- Harris NL, Jaffe E, Stein H. A revised European-American Classification of Lymphoid Neoplasms: a proposal From the International Lymphoma Study Group. Blood 1994; 84: 1361.

  11. 11.- Jaffe ES, Harris NL, Stein H. Pathology and genetics of Tumors of haemopoietic and Lymphoid Tissues.Hodgkin Lymphoma. Lyon Press 2001; 237.

  12. 12.- Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31 (11): 1860.

  13. 13.- Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54: 208-36.

  14. 14.- National Cancer Institute. Clasificación de las neoplasias linfoides, REAL/OMS actualizada, septiembre 2013. [Consultado septiembre 2014]. Disponible en: http://www.cancer.gov/espanol/pdq/tratamiento/hodgkindi sease/ HealthProfessional/page3.




2020     |     www.medigraphic.com